250 related articles for article (PubMed ID: 33724119)
21. A Novel Nonhormonal Treatment for Vasomotor Symptoms of Menopause.
Javernick JA
Nurs Womens Health; 2024 Feb; 28(1):80-84. PubMed ID: 38161058
[TBL] [Abstract][Full Text] [Related]
22. Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial.
Yu Q; Ming F; Ma J; Cai Y; Wang L; Ren M; Zhang J; Ma X; Miyazaki K; He W; Wang X
J Int Med Res; 2024 May; 52(5):3000605241246624. PubMed ID: 38818887
[TBL] [Abstract][Full Text] [Related]
23. Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants.
Elhusein AM; Fadlalmola HA; Abedelwahed HH; Elshaikh AA; Banaga AE; Alrahman MHF; Abdelgadim NH; Mohammed IH; Abdalla AAA; Abdalla FAM; Abd Allah EM; Abbas NI; Alhujaili AD; Almkiy EA; Idress EA; Awadalkareem EM; Abdeldafie SY; Balusamy P; Mohamed RA; Aloufi RSM; Habiballa M; Abdelmalik MA; Alhejaili MM; Ibrahim IA; Masaad HK
Afr J Reprod Health; 2024 Mar; 28(3):99-113. PubMed ID: 38583073
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).
Ruan X; Bai W; Ren M; Kim T; Lee JY; Chuang FC; Wang PH; He W; Ma X; Miyazaki K; Song N; Wang X; Yu Q
J Int Med Res; 2024 May; 52(5):3000605241247684. PubMed ID: 38818888
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
Akhtar SMM; Ali A; Khan MS; Khan V; Fareed A; Saleem SZ; Mumtaz M; Ahsan MN; Iqbal S; Asghar MS
Int J Gynaecol Obstet; 2024 Apr; ():. PubMed ID: 38563867
[TBL] [Abstract][Full Text] [Related]
26. Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms.
Sassarini J; Anderson RA
Expert Opin Investig Drugs; 2024 Jan; 33(1):19-26. PubMed ID: 38224099
[TBL] [Abstract][Full Text] [Related]
27. Neurokinin 3 receptor antagonism for menopausal hot flashes.
Comninos AN; Dhillo WS
Cell; 2023 Aug; 186(16):3332-3332.e1. PubMed ID: 37541194
[TBL] [Abstract][Full Text] [Related]
28. Insights into the genetics of menopausal vasomotor symptoms: genome-wide analyses of routinely-collected primary care health records.
Ruth KS; Beaumont RN; Locke JM; Tyrrell J; Crandall CJ; Hawkes G; Frayling TM; Prague JK; Patel KA; Wood AR; Weedon MN; Murray A
BMC Med Genomics; 2023 Oct; 16(1):231. PubMed ID: 37784116
[TBL] [Abstract][Full Text] [Related]
29. Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review.
Menown SJ; Tello JA
Adv Ther; 2021 Oct; 38(10):5025-5045. PubMed ID: 34514552
[TBL] [Abstract][Full Text] [Related]
30. Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms.
Pinkerton JV; Redick DL; Homewood LN; Kaunitz AM
J Clin Endocrinol Metab; 2023 Oct; 108(11):e1448-e1449. PubMed ID: 37097747
[No Abstract] [Full Text] [Related]
31. Fezolinetant (Veozah) for menopausal vasomotor symptoms.
Med Lett Drugs Ther; 2023 Jun; 65(1679):97-99. PubMed ID: 37339088
[No Abstract] [Full Text] [Related]
32. Scaffold hopping of fused piperidine-type NK3 receptor antagonists to reduce environmental impact.
Yamamoto K; Inuki S; Ohno H; Oishi S
Bioorg Med Chem; 2019 May; 27(10):2019-2026. PubMed ID: 30975505
[TBL] [Abstract][Full Text] [Related]
33. FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research.
Rani P; Zehra D; Mansoor M; Rani P
Arch Womens Ment Health; 2024 Mar; ():. PubMed ID: 38478035
[TBL] [Abstract][Full Text] [Related]
34. "Veozah (Fezolinetant): A Promising Non-Hormonal Treatment for Vasomotor Symptoms in Menopause".
Shaukat A; Mujeeb A; Shahnoor S; Nasser N; Khan AM
Health Sci Rep; 2023 Oct; 6(10):e1610. PubMed ID: 37808928
[TBL] [Abstract][Full Text] [Related]
35. Neurokinin B and Neurokinin-3 Receptor Signaling: Promising Developments in the Management of Menopausal Hot Flushes.
Modi M; Dhillo WS
Semin Reprod Med; 2019 May; 37(3):125-130. PubMed ID: 31869840
[TBL] [Abstract][Full Text] [Related]
36. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).
Nappi RE; Johnson KA; Stute P; Blogg M; English M; Morga A; Scrine L; Siddiqui E; Ottery FD
Menopause; 2024 Jun; 31(6):512-521. PubMed ID: 38626380
[TBL] [Abstract][Full Text] [Related]
37. Neurokinin 3 receptor antagonists - prime time?
Prague JK
Climacteric; 2021 Feb; 24(1):25-31. PubMed ID: 33135940
[TBL] [Abstract][Full Text] [Related]
38. A review of paroxetine for the treatment of vasomotor symptoms.
Slaton RM; Champion MN; Palmore KB
J Pharm Pract; 2015 Jun; 28(3):266-74. PubMed ID: 25107421
[TBL] [Abstract][Full Text] [Related]
39. Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.
Cano A; Nappi RE; Santoro N; Stute P; Blogg M; English ML; Morga A; Scrine L; Siddiqui E; Ottery FD
BJOG; 2024 Feb; ():. PubMed ID: 38320967
[TBL] [Abstract][Full Text] [Related]
40. Neurokinin 3 receptor antagonism - the magic bullet for hot flushes?
Prague JK; Dhillo WS
Climacteric; 2017 Dec; 20(6):505-509. PubMed ID: 29040006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
